ReviewTechnology in cancer research & treatment
The Rise of Generalist Foundation Models and Quantum Computing in Oncology.
Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.